Literature DB >> 11700053

Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage.

L Urbanelli1, C Ronchini, L Fontana, S Menard, R Orlandi, P Monaci.   

Abstract

Screening a random peptide library displayed on phage as fusion to the major capsid protein pVIII identified a ligand binding the human epidermal growth factor receptor 2 (HER2) specifically. By mutating the sequence of this ligand, a "secondary" library was generated, whose panning on HER2-positive cells isolated a phage-borne peptide with increased specific binding to HER2 (phage NL1.1). The same peptide recognised HER2 specifically when expressed as an N-terminal fusion to the minor coat protein pIII. Phage NL1.1 was engineered to include a mammalian expression cassette for a reporter gene within its genome. This modified phage transduced HER2-expressing cells with very high specificity (more than 1000-fold that of parental HER2-negative cells) and with an efficiency comparable to that of chemical transfection protocols. The gene delivery process was remarkably fast, requiring less than 15 minutes incubation of phage with target cells to generate detectable levels of gene expression. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700053     DOI: 10.1006/jmbi.2001.5111

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Authors:  Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

Review 2.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

Authors:  Kathlynn C Brown
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  A simple method for displaying recalcitrant proteins on the surface of bacteriophage lambda.

Authors:  Christine N Zanghi; Heather A Lankes; Birgit Bradel-Tretheway; Jessica Wegman; Stephen Dewhurst
Journal:  Nucleic Acids Res       Date:  2005-10-13       Impact factor: 16.971

4.  Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system.

Authors:  Olusegun A Fagbohun; Robert A Kazmierczak; Valery A Petrenko; Abraham Eisenstark
Journal:  J Nanobiotechnology       Date:  2013-09-23       Impact factor: 10.435

5.  Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand.

Authors:  Arun Vaidyanath; Toshihiro Hashizume; Tadahiro Nagaoka; Nao Takeyasu; Hitomi Satoh; Ling Chen; Jiyou Wang; Tomonari Kasai; Takayuki Kudoh; Ayano Satoh; Li Fu; Masaharu Seno
Journal:  J Cell Mol Med       Date:  2011-11       Impact factor: 5.310

6.  Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics.

Authors:  Kelsey J Weigel; Luqun Shen; Clayton L Thomas; Daniel Alber; Lauren Drapalik; Zachary T Schafer; Shaun W Lee
Journal:  FEBS Open Bio       Date:  2015-03-14       Impact factor: 2.693

7.  Cellular uptake, intracellular distribution and degradation of Her2-targeting silk nanospheres.

Authors:  Anna Florczak; Andrzej Mackiewicz; Hanna Dams-Kozlowska
Journal:  Int J Nanomedicine       Date:  2019-08-26

8.  Killing cancer cells by targeted drug-carrying phage nanomedicines.

Authors:  Hagit Bar; Iftach Yacoby; Itai Benhar
Journal:  BMC Biotechnol       Date:  2008-04-03       Impact factor: 2.563

9.  Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells.

Authors:  Mouldy Sioud; Phuong Westby; Julie Kristine E Olsen; Anne Mobergslien
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-04       Impact factor: 6.698

10.  A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids.

Authors:  Yu-Hsiu Su; Tai-Yun Lin; Hung-Jen Liu; Chin-Kai Chuang
Journal:  Oncotarget       Date:  2018-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.